With PDL1 as a positive predictive biomarker, it has been shown that in subgroups of patients with raised PDL1 combined positive score (CPS) or tumour proportion score (TPS), ICI and chemotherapy combination outperforms chemotherapy in disease control and progression-free survival (PFS) (178). The gene discussed is CD274; the disease is neoplasm.